Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.33 |
| ▸ | FDPS | P14324 | 4/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27730244 | 0.98 | HRH3 (0.37) | HRH3L3MBTL1MAPTMAPK1NPSR1 | |
| SCHEMBL27396815 | 0.98 | HRH3 (0.37) | HRH3L3MBTL1MAPTMAPK1NPSR1 | |
| SCHEMBL27531714 | 0.98 | HRH3 (0.37) | HRH3L3MBTL1MAPTMAPK1NPSR1 | |
| SCHEMBL27919855 | 0.98 | HRH3 (0.37) | HRH3L3MBTL1MAPTMAPK1NPSR1 | |
| SCHEMBL27801806 | 0.98 | HRH3 (0.37) | HRH3L3MBTL1MAPTMAPK1NPSR1 | |
| SCHEMBL23733430 | 0.98 | HRH3 (0.37) | HRH3L3MBTL1MAPTMAPK1NPSR1 | |
| SCHEMBL27321157 | 0.98 | HRH3 (0.37) | HRH3L3MBTL1MAPTMAPK1NPSR1 | |
| SCHEMBL27953379 | 0.98 | HRH3 (0.36) | HRH3L3MBTL1MAPTMAPK1NPSR1 | |
| Iodide SCHEMBL15008385 | 0.96 | HRH3 (0.35) | HRH3L3MBTL1MAPTMAPK1NPSR1 | |
| SCHEMBL27919858 | 0.96 | FDPS (0.36) | HRH3L3MBTL1MAPTMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117043136-A | Fluorine-based ionic liquid and method for producing same | 第一工业制药株式会社 | 2023-11-10 | — | — | CN | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210317097-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2021-10-14 | — | — | US | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| CN-109628004-A | Film, surface protective film and optical component with finishing coat | 日东电工株式会社 | 2019-04-16 | — | — | CN | disclosed |
| CN-103827246-B | Adhesive composition, adhesive layer, adhesive sheet, surface protection sheet, optical surface protection sheet, and optical film with surface protection sheet | 日东电工株式会社 | 2018-06-01 | — | — | CN | disclosed |
| US-20100178333-A1 | SUSTAINED RELEASE DOSAGE FORM OF PHENOTHIAZINE DERIVATIVES CONTAINING CHANNELIZER | ASTRON RESEARCH LIMITED (IN) | 2010-07-15 | — | — | US | disclosed |
| EP-1976487-A2 | SUSTAINED RELEASE DOSAGE FORM OF PHENOTHIAZINE DERIVATIVES CONTAINING CHANNELIZER | Astron Research Limited (IN) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007086079-A2 | SUSTAINED RELEASE DOSAGE FORM OF PHENOTHIAZINE DERIVATIVES CONTAINING CHANNELIZER | ASTRON RESEARCH LIMITED (IN) | 2007-08-02 | — | — | WO | disclosed |
| CN-1840600-A | Adhesive composition, adhesive sheets and surface protective film | NITTO DENKO CORP (JP) | 2006-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317097-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | HRH3 3554/4885L3MBTL1 2364/4885MAPT 2165/4885 |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | HRH3 3554/4885L3MBTL1 2364/4885MAPT 2165/4885 |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | HRH3 4469/4885L3MBTL1 797/4885MAPT 1670/4885 |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | MAPK1, MAPK8, MAPK4 | HRH3 3554/4885L3MBTL1 2364/4885MAPT 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.